ProHealth health Vitamin and Natural Supplement Store and Health
Home  |  Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help
Facebook Google Plus
Fibromyalgia  Chronic Fatigue Syndrome & M.E.  Lyme Disease  Natural Wellness  Supplement News  Forums  Our Story
Store     Brands   |   A-Z Index   |   Best Sellers   |   New Products   |   Deals & Specials   |   Under $10   |   SmartSavings Club

Trending News

Can Autoimmune Conditions be Reversed? Researchers Make a Surprising Discovery

How One Tiny Molecule Turned into One Huge Health Breakthrough

Nutrients Boost Stem Cell Function

Humans have three times more brown body fat

B12 Proven Essential for Every Cell

Soy isoflavones may benefit breast cancer patients

How B Vitamins Improve Brain Health, Cognition, Psychiatric Problems and Mood Disorders

Dietary prebiotics improve sleep, buffer impacts of stress, says study

Ylang Ylang Oil Not Only Soothes Your Skin, but Your Mind as Well

Exercises to Help Prevent Urinary Incontinence

 
Print Page
Email Article

Using Innovative Funding Mechanisms to Discover, Develop, and Test a Potentially Promising AD Drug

  [ Not Yet Rated ]   [ Discuss This Article ]
By 1999 Progress Report by the NIA/NIH • www.ProHealth.com • December 13, 1999


AIT-082 is a novel small molecule that crosses the blood-brain barrier to enhance nerve function. It does this by increasing the levels of nerve growth factors and encouraging nerve sprouting in the brain. The process that AIT-082 has gone through--from initial discovery to tests in humans--illustrates well the way in which NIA's innovative funding mechanisms work together to foster the development of potentially promising drug treatments for AD.

A Small Business Innovation Research Grant (SBIR) was the first NIH step for AIT-082. This grant allowed scientists to develop the compound and conduct initial tests on its function. Based on the promising results from this work, NIA provided funds through the Investigational New Drug Toxicology for Drugs to Treat Alzheimer's Disease contract mechanism to begin the formal drug testing process. The studies showed that AIT-082 did not have an adverse toxicologic effect in laboratory animals. The National Institute of Mental Health also contributed to this effort by providing support through a contract to synthesize sufficient quantities of AIT-082 for the toxicologic testing.

These results allowed researchers to take the step from animal tests to tests in humans, and NIA is currently supporting Phase I clinical trials of AIT-082. In Phase 1 studies, a small number of volunteers are given a drug to assess safety at various doses and establish some initial indication of effectiveness. The studies have been conducted through the Alzheimer's Disease Cooperative Study at four Alzheimer's Disease Centers sites (the University of California at San Diego, Indiana University, the University of Michigan, and Washington University in St. Louis). In a Phase IA study, eight healthy older volunteers were given single, weekly, increasing doses of AIT-082 or a placebo for 5 weeks. During that time they were tested for side effects and for whether they properly absorbed the drug. They also underwent a battery of neuropsychological memory tests, including word and number recall tests. The study period is complete and the research team is now analyzing the results. A Phase IB study is currently ongoing in which safety and initial effectiveness is being assessed in 36 people with AD.

If the results show that AIT-082 is both safe and has some indication of effectiveness, the next step will be to test the drug in a larger clinical trial for its effect on AD symptoms, development, or progression.

Source:
National Institutes of Health
National Institute on Aging
1999 PROGRESS REPORT ON ALZHEIMER'S DISEAS



Post a Comment

Featured Products From the ProHealth Store
Ultra ATP+, Double Strength Optimized Curcumin Longvida® Mitochondria Ignite™ with NT Factor®

Looking for Vitamins, Herbs and Supplements?
Search the ProHealth Store for Hundreds of Natural Health Products


Article Comments



Be the first to comment on this article!

Post a Comment


 
NAD+ Ignite with Niagen

Featured Products

Mitochondria Ignite™ with NT Factor® Mitochondria Ignite™ with NT Factor®
Reduce Fatigue up to 45%
Ultra ATP+, Double Strength Ultra ATP+, Double Strength
Get energized with malic acid & magnesium
FibroSleep™ FibroSleep™
The All-in-One Natural Sleep Aid
Energy NADH™ 12.5mg Energy NADH™ 12.5mg
Improve Energy & Cognitive Function
Ultra EPA  - Fish Oil Ultra EPA - Fish Oil
Ultra concentrated source of essential fish oils

Natural Remedies

The Revolutionary 'Good Fat' That Promotes Heart, Brain, Bone and Joint Health The Revolutionary 'Good Fat' That Promotes Heart, Brain, Bone and Joint Health
Coenzyme Q10 - The Energy Maker Coenzyme Q10 - The Energy Maker
The Remarkable Benefits of Reishi Medicinal Mushrooms The Remarkable Benefits of Reishi Medicinal Mushrooms
SAD? Coping with Seasonal Affective Disorder SAD? Coping with Seasonal Affective Disorder
Coping When Colds or Flu Catch Up with You Coping When Colds or Flu Catch Up with You

CONTACT US
ProHealth, Inc.
555 Maple Ave
Carpinteria, CA 93013
(800) 366-6056  |  Email

· Become a Wholesaler
· Vendor Inquiries
· Affiliate Program
SHOP WITH CONFIDENCE
Credit Card Processing
SUBSCRIBE TO OUR NEWSLETTERS
Get the latest news about Fibromyalgia, M.E/Chronic Fatigue Syndrome, Lyme Disease and Natural Wellness

CONNECT WITH US ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus

© 2017 ProHealth, Inc. All rights reserved. Pain Tracker App  |  Store  |  Customer Service  |  Guarantee  |  Privacy  |  Contact Us  |  Library  |  RSS  |  Site Map